Riociguat

Riociguat is methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridin-3-yl]-5-pyrimidinyl(methyl carbamate. It is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with Persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class.It is also indicated for Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class and to delay clinical worsening.

Brands

Adult Dose

Neonatal

Paedriatic

Characteristics

. It is of Synthetic origin. . The Molecular Weight of Riociguat is 422.42.

Contraindications

Riociguat

Effects

The symptomatic adverse reactions produced by Riociguat are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Nausea, Vomiting, Diarrhea, Constipation, Gastritis, Dyspepsia, Hypotension, Anemia, dizziness, dyspepsia, Hypotension, GI reflux.

Indications

Riociguat is primarily indicated in conditions like Pulmonary hypertension.

Interactions

No data regarding the interactions of Riociguat was found.

Interfrence

Risks

Drug should not be given to Paediatrics, Pregnant Mothers, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Storage

Tablet Store Between 15°C-30°C.

Warnings

Symptomatic hypotension , Bleeding , Pulmonary edema in patients with pulmonary veno-occlusive disease. If confirmed, discontinue treatment.

Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.